HTB South

Resistance

Pre-ART drug resistance in rural South Africa but limited clinical impact with good adherence

No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial

Prevalence of transmitted drug resistance globally: highest in Australia, US and some European countries but between-country differences in all regions

Higher rates of K65R in non-B subtype in large UK cohort and implications of tenofovir resistance in resource-limited settings

Drug resistance and integrase inhibitors: potential impact of HIV subtype

Drug resistance in children after PMTCT and early treatment

Genotyping using dried blood spots in rural South African setting

NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

Persistence of transmitted drug resistance mutations suggests source partners may be treatment-naive

Dolutegravir update: treatment-naive and -experienced patients and drug resistance

Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro

Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance

S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir

ddI resistance in South African children failing an abacavir or d4T based first-line regimen

US label changes for rilpivirine and Eviplera follows EU caution on high baseline viral load: new summary on drug resistance

In vitro resistance profile for BMS 986001

Recombination dynamics in case of MDR sub-type D following superinfection with wild-type sub-type B

Defective viral reservoir populations is common in patients on long-term suppressed ART

First case report of transmission with five-class resistance

New data on the Berlin patient: interpret with caution

Free online resource for treatment decisions without access to genotype resistance tests

No significant difference in virological failure found between once-yearly versus twice-yearly viral load monitoring in Thai study

Model predicts rate of transmitted drug resistant virus in resource-limited settings

Rate of accumulation of TAMS slow in patients continuing on failing AZT or d4T containing regimens